Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000102909-25-000236
Filing Date
2025-10-31
Accepted
2025-10-31 11:03:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4506
  Complete submission text file 0000102909-25-000236.txt   6383
Mailing Address PO BOX 2600 V26 VALLEY FORGE PA 19482-2600
Business Address 100 VANGUARD BLVD MALVERN PA 19355 6106691000
VANGUARD GROUP INC (Filed by) CIK: 0000102909 (see all company filings)

EIN.: 231945930 | State of Incorp.: PA | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Subject) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-84250 | Film No.: 251438797
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)